Reported Friday, Cellectar Biosciences Announces Plan To Restate Financials, Delays 10-Q Filing, And Receives Nasdaq Non-Compliance Notification
Reported Friday, Cellectar Biosciences Announces Plan To Restate Financials, Delays 10-Q Filing, And Receives Nasdaq Non-Compliance Notification
據報道，cellectar biosciences宣佈計劃重新陳述財務報表，延遲10-q申報，並收到納斯達克的違規通知。
- The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the "Second Quarter 10-Q"), by the applicable due date.
- The delay in filing the Second Quarter 10-Q is a result of the Company's need to restate certain previously filed financial statements.
- 通知顯示，由於公司延遲報告截至2024年6月30日季度的第二季度10-Q表格，導致公司未能遵守納斯達克上市規則5250(c)(1)中規定的定期財務報告提交要求。
- 延遲提交第二季度10-Q表格是因爲公司需要重新編制某些先前提交的基本報表。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。